Improvement in Quality of Life With Left Prefrontal Transcranial Magnetic Stimulation in Patients With Pharmacoresistant Major Depression: Acute and Six Month Outcomes |
| |
| Affiliation: | 1. Department of Psychiatry, Stanford University Medical Center, Stanford University, 401 Quarry Road, Palo Alto, CA 94305 USA;2. University of Texas Southwestern Medical School, Dallas, TX, USA;3. The Alfred Hospital, Melbourne, Australia;4. Medical College of Georgia, Augusta, GA, USA;5. Wake Forest University, Winston-Salem, NC, USA;6. Northwestern University, Chicago, IL, USA;7. Neuronetics, Inc., Malvern, PA, USA;8. Duke University, Durham, NC, USA;1. Department of Psychiatry and Psychotherapy, Neurophysiology & Interventional Neuropsychiatry, University of Tübingen, Calwerstrasse 14, Tübingen D-72076, Germany;2. Medical Statistics & Information Technology, AFaR, Fatebenefratelli Hospital, Isola Tiberina, Rome;1. Université de Lyon, Université Claude Bernard Lyon I, EA 4615, Centre Hospitalier le Vinatier, Bron F-69003, France;2. CHU Clermont-Ferrand, Service de Psychiatrie de l''Adulte A et Psychologie médicale, F-63003 Clermont-Ferrand, France;3. Clermont Université, Université d''Auvergne Clermont 1, UFR Médecine, Equipe d''Accueil 7280, F-63001 Clermont-Ferrand, France;4. CHU Dijon, Hôpital Général, Service de Psychiatrie et d''Addictologie, 21000 Dijon, France;5. CHU Hôpital La Colombière, 34000 Montpellier, France;6. Fonctions cérébrales et neuromodulation, Grenoble Institut des Neurosciences, Université Joseph Fourier, Grenoble, France;7. Clinique Universitaire de Psychiatrie, Pôle Psychiatrie-Neurologie, Centre Hospitalier Universitaire, Grenoble, France;8. UMS IRMaGe, Grenoble, France;9. CHU St Etienne, Hôpital Nord, 42055 St Etienne Cedex, France;10. EPS de Ville Evrard, Unité de Saint-Denis, 93200 Saint-Denis, France;11. CHU Besançon, Department of Clinical Psychiatry, University Hospital, 25000 Besançon, France;12. Pôle “Information Médicale Evaluation Recherche” (IMER) 62 Avenue Lacassagne Bât A, 69424 Lyon cedex 03 CHU Lyon, France;13. CHU Lyon, Service de psychiatrie des urgences, Hôpital Edouard Herriot, Lyon, France;1. Department of Psychiatry and Addictology, University Hospital of Dijon, France;2. EA 4452, LPPM, University of Burgundy, France;3. Clinical Research Department, University Hospital of Dijon, France;4. Department of Psychiatry, University Hospital of Besançon, France;5. CSAPA University Hospital of Nancy, France;6. Department of Psychiatry, Centre Psychothérapique de Nancy, Laxou, France;1. Department of Psychiatry and Biobehavioral Sciences and Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;2. Department of Psychiatry, UCSD School of Medicine, San Diego, CA, USA;3. Institute of Living, Hartford Hospital, Hartford, CT, USA;4. Department of Psychiatry, UT Southwestern Medical School, Dallas, TX, USA;5. Department of Psychiatry and Human Behavior, Butler Hospital, Alpert Medical School of Brown University, Providence, RI, USA;6. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;7. Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA;8. Department of Psychiatry, University of Nebraska School of Medicine, Omaha, NE, USA;9. Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA;10. Department of Psychiatry, School of Medicine, Washington University, St. Louis, MO, USA;11. Sheppard Pratt Health System, Baltimore, MD, USA;12. Department of Psychiatry, Icahn School of Medicine at Mt. Sinai, New York, NY, USA;13. Department of Psychiatry, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA;14. Chicago TMS Specialists, Chicago, IL, USA;15. RD Clinical Research, Lake Jackson, TX, USA;p. Harbor-UCLA Medical Center, Torrance, CA, USA;q. Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA;r. Department of Psychiatry, Medical University of South Carolina, and the Ralph H. Johnson VA Medical Center, Charleston, SC, USA;s. NeoSync, Inc., Waltham, MA, USA;t. NeoSync, Inc., Newport Beach, CA, USA;1. Laboratory of Brain and Cognition, 4804 Montgomery Avenue, Bethesda, MD 20814, USA;2. Behavioral Neurology Unit, NINDS, NIH, DHHS, USA;3. Mood and Anxiety Disorder Branch, NIMH, NIH, DHHS, USA;4. PET Department, Clinical Center, NIH, DHHS, USA;5. Bipolar Collaborative Network, 5415 W. Cedar Lane, Suite 201-B, Bethesda, MD 20814, USA;1. Department of Psychiatry and Medical Psychology, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium;2. University Hospital (UZBrussel), Department of Psychiatry, Brussels, Belgium;3. Ghent Experimental Psychiatry (GHEP) Lab, Ghent University, Ghent, Belgium;4. Department of Experimental Clinical and Health Psychology, Ghent University, Ghent, Belgium |
| |
| Abstract: | ![]()
BackgroundTranscranial magnetic stimulation (TMS) is a safe and effective treatment for major depression. We describe quality of life (QOL) outcomes from acute treatment with TMS, and describe the durability of benefit across 24-weeks.MethodsThree hundred and one medication-free patients with pharmacoresistant major depression were randomized to active or sham TMS in a 6-week controlled trial. Nonresponders to the 6-week blinded phase of the study were enrolled in a 6-week open-label study without unblinding the prior treatment assignment. Responders and partial responders to both the blinded (active or sham treatment) or open acute treatment phases were tapered off TMS over three weeks, while initiating maintenance antidepressant medication monotherapy. These subjects entered the 24-week study to examine the durability of response to TMS. The Medical Outcomes Study-36 Item Short Form (SF-36) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used to measure overall function and QOL. During the 24-week durability of effect study, QOL assessments were done at study entry and at the end of 24-weeks.ResultsStatistically significant improvement in both functional status and QOL outcomes was observed in patients treated with active TMS compared with sham TMS during the acute phase of the randomized, sham-controlled trial. Similar benefits were observed in patients who entered the open-label extension study. These improvements were sustained across the 24-week follow up study.ConclusionsAcute treatment with TMS improved functional status and QOL outcomes in patients with major depression. This clinical effect was durable in long-term follow up. |
| |
| Keywords: | Quality of life Antidepressant TMS Clinical trial Major depression Treatment resistance |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
